Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Fachpsychotherapie Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Current Treatment Options in Pediatrics
Erschienen in:

01.12.2025 | Pediatric Infectious Disease (M Mitchell and F Zhu, Section Editors)

Updates in the Treatment of Kawasaki Disease

verfasst von: Bessey Geevarghese

Erschienen in: Current Treatment Options in Pediatrics | Ausgabe 1/2025

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Kawasaki disease is the leading cause of childhood-onset acquired heart disease in developed countries, and if left untreated, leads to complications of coronary artery aneurysms (CAA) in approximately 25% of cases. While the gold standard treatment remains intravenous immunoglobulin (IVIG) and aspirin (ASA), there remains a lack of evidence for choosing optimal treatment for high-risk and refractory cases. This article summarizes the current recommendations for initial therapy and reviews the latest research and guidelines regarding anti-inflammatory treatment to minimize the incidence of coronary artery lesions.

Recent Findings

Recent studies suggest that an antiplatelet dose of ASA, when administered with IVIG, is not inferior to higher ASA doses in reducing the risk of coronary artery abnormalities. Corticosteroids and infliximab are currently two agents that have been studied the most in patients deemed to be at higher risk or in those who fail to respond to IVIG. Also, only corticosteroids have proved effective in decreasing the incidence of CAA in a randomized trial in high-risk Japanese population.

Summary

The ongoing challenge continues to be early identification of high-risk Kawasaki patients in all ethnic populations who would benefit from intensified primary therapy.
Literatur
1.
Burns JC. Commentary: translation of Dr. Tomisaku Kawasaki’s original report of fifty patients in 1967. Pediatr Infect Dis J. 2002;21(11):993–5.PubMedCrossRef
2.
McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135(17):e927–99.PubMedCrossRef
3.
4.
Rowley AH, Shulman ST, Mask CA, Finn LS, Terai M, Baker SC, et al. IgA plasma cell infiltration of proximal respiratory tract, pancreas, kidney, and coronary artery in acute Kawasaki disease. J Infect Dis. 2000;182(4):1183–91.PubMedCrossRef
5.
Rowley AH, Baker SC, Shulman ST, Garcia FL, Fox LM, Kos IM, et al. RNA-containing cytoplasmic inclusion bodies in ciliated bronchial epithelium months to years after acute Kawasaki disease. PLoS One. 2008;3(2):e1582.PubMedPubMedCentralCrossRef
6.
Burney JA, Roberts SC, DeHaan LL, Shimizu C, Bainto EV, Newburger JW, et al. Epidemiological and clinical features of Kawasaki disease during the COVID-19 pandemic in the United States. JAMA Netw Open. 2022;5(6):e2217436.PubMedPubMedCentralCrossRef
7.
Shulman S, Geevarghese B, Kim KY, Rowley A. The impact of social distancing for COVID-19 upon diagnosis of Kawasaki disease. J Pediatr Infect Dis Soc. 2021;10(6):742–4.CrossRef
8.
Iio K, Matsubara K, Miyakoshi C, Ota K, Yamaoka R, Eguchi J, et al. Incidence of Kawasaki disease before and during the COVID-19 pandemic: a retrospective cohort study in Japan. BMJ Paediatr Open. 2021;5(1):e001034.PubMedPubMedCentralCrossRef
9.
Kang JM, Kim YE, Huh K, Hong J, Kim DW, Kim MY, et al. Reduction in Kawasaki disease after nonpharmaceutical interventions in the COVID-19 Era: a nationwide observational study in Korea. Circulation. 2021;143(25):2508–10.PubMedPubMedCentralCrossRef
10.
11.
Belay ED, Maddox RA, Holman RC, Curns AT, Ballah K, Schonberger LB. Kawasaki syndrome and risk factors for coronary artery abnormalities: United States, 1994–2003. Pediatr Infect Dis J. 2006;25(3):245–9.PubMedCrossRef
12.
Burns JC, Shike H, Gordon JB, Malhotra A, Schoenwetter M, Kawasaki T. Sequelae of Kawasaki disease in adolescents and young adults. J Am Coll Cardiol. 1996;28(1):253–7.PubMedCrossRef
13.
Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986;315(6):341–7.PubMedCrossRef
14.
15.
Eleftheriou D, Levin M, Shingadia D, Tulloh R, Klein NJ, Brogan PA. Management of Kawasaki disease. Arch Dis Child. 2014;99(1):74–83.PubMedCrossRef
16.
Bratincsak A, Reddy VD, Purohit PJ, Tremoulet AH, Molkara DP, Frazer JR, et al. Coronary artery dilation in acute Kawasaki disease and acute illnesses associated with fever. Pediatr Infect Dis J. 2012;31(9):924–6.PubMedCrossRef
17.
Newburger JW, Takahashi M, Burns JC. Kawasaki disease. J Am Coll Cardiol. 2016;67(14):1738–49.PubMedCrossRef
18.
Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991;324(23):1633–9.PubMedCrossRef
19.
Morikawa Y, Ohashi Y, Harada K, Asai T, Okawa S, Nagashima M, et al. A multicenter, randomized, controlled trial of intravenous gamma globulin therapy in children with acute Kawasaki disease. Acta Paediatr Jpn. 1994;36(4):347–54.PubMedCrossRef
20.
Dominguez SR, Anderson MS, El-Adawy M, Glodé MP. Preventing coronary artery abnormalities: a need for earlier diagnosis and treatment of Kawasaki disease. Pediatr Infect Dis J. 2012;31(12):1217–20.PubMedCrossRef
21.
Oates-Whitehead RM, Baumer JH, Haines L, Love S, Maconochie IK, Gupta A, et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. 2003;2003(4):CD004000.PubMedPubMedCentral
22.
23.
van Stijn D, Korbee JM, Netea SA, de Winter VC, Zwinderman KAH, Kuipers IM, et al. Treatment and coronary artery aneurysm formation in Kawasaki disease: a per-day risk analysis. J Pediatr. 2022;243:167-72.e1.PubMedCrossRef
24.
Nolan BE, Wang Y, Pary PP, Luban NLC, Wong ECC, Ronis T. High-dose intravenous immunoglobulin is strongly associated with hemolytic anemia in patients with Kawasaki disease. Transfusion. 2018;58(11):2564–71.PubMedCrossRef
25.
Morikawa Y, Sakakibara H, Kimiya T, Obonai T, Miura M, Tokyo Pediatric Clinical Research N. Live attenuated vaccine efficacy six months after intravenous immunoglobulin therapy for Kawasaki disease. Vaccine. 2021;39(39):5680–7.PubMedCrossRef
26.
Research Committee of the Japanese Society of Pediatric C, Cardiac Surgery Committee for Development of Guidelines for Medical Treatment of Acute Kawasaki D. Guidelines for medical treatment of acute Kawasaki disease: report of the research committee of the japanese society of pediatric cardiology and cardiac surgery (2012 revised version). Pediatr Int. 2014;56(2):135–58.CrossRef
27.
Ogata S, Tremoulet AH, Sato Y, Ueda K, Shimizu C, Sun X, et al. Coronary artery outcomes among children with Kawasaki disease in the United States and Japan. Int J Cardiol. 2013;168(4):3825–8.PubMedPubMedCentralCrossRef
28.
Lang B, Duffy CM. Controversies in the management of Kawasaki disease. Best Pract Res Clin Rheumatol. 2002;16(3):427–42.PubMedCrossRef
29.
Fukazawa R, Kobayashi J, Ayusawa M, Hamada H, Miura M, Mitani Y, et al. JCS/JSCS 2020 guideline on diagnosis and management of cardiovascular sequelae in Kawasaki disease. Circ J. 2020;84(8):1348–407.PubMedCrossRef
30.
Kuo HC, Lo MH, Hsieh KS, Guo MM, Huang YH. High-dose aspirin is associated with anemia and does not confer benefit to disease outcomes in Kawasaki disease. PLoS One. 2015;10(12):e0144603.PubMedPubMedCentralCrossRef
31.
Saulsbury FT. Comparison of high-dose and low-dose aspirin plus intravenous immunoglobulin in the treatment of Kawasaki syndrome. Clin Pediatr (Phila). 2002;41(8):597–601.PubMedCrossRef
32.
Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM. Treatment of acute Kawasaki disease: aspirin’s role in the febrile stage revisited. Pediatrics. 2004;114(6):e689–93.PubMedCrossRef
33.
34.
Dallaire F, Fortier-Morissette Z, Blais S, Dhanrajani A, Basodan D, Renaud C, et al. Aspirin dose and prevention of coronary abnormalities in Kawasaki disease. Pediatrics. 2017;139(6).
35.
Wu Y, Hu L, Xie X, Li W, Wang Y, Zhang L, et al. Different dose aspirin plus immunoglobulin (DAPI) for prevention of coronary artery abnormalities in Kawasaki disease: study protocol for a multi-center, prospective, randomized, open-label, blinded end-point, non-inferiority trial. Am Heart J. 2024;273:1–9.PubMedCrossRef
36.
Kuo HC, Lin MC, Kao CC, Weng KP, Ding Y, Chen CJ, et al. Efficacy of Intravenous Immunoglobulin Alone on Coronary Artery Lesion Reduction in Kawasaki Disease. medRxiv. 2024.
37.
Geevarghese B, Shulman S. Common cardiac issues in pediatrics. In: Kamat D  Johnson J, editors. Kawasaki Disease. American Academy Pediatrics; 2018. pp. 423–442.
38.
Galeotti C, Kaveri SV, Cimaz R, Koné-Paut I, Bayry J. Predisposing factors, pathogenesis and therapeutic intervention of Kawasaki disease. Drug Discov Today. 2016;21(11):1850–7.PubMedPubMedCentralCrossRef
39.
Kobayashi T, Inoue Y, Takeuchi K, Okada Y, Tamura K, Tomomasa T, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation. 2006;113(22):2606–12.PubMedCrossRef
40.
Egami K, Muta H, Ishii M, Suda K, Sugahara Y, Iemura M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr. 2006;149(2):237–40.PubMedCrossRef
41.
Sano T, Kurotobi S, Matsuzaki K, Yamamoto T, Maki I, Miki K, et al. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr. 2007;166(2):131–7.PubMedCrossRef
42.
Kim MK, Song MS, Kim GB. Factors predicting resistance to intravenous immunoglobulin treatment and coronary artery lesion in patients with Kawasaki disease: analysis of the Korean nationwide multicenter survey from 2012 to 2014. Korean Circ J. 2018;48(1):71–9.PubMedCrossRef
43.
Sleeper LA, Minich LL, McCrindle BM, Li JS, Mason W, Colan SD, et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr. 2011;158(5):831-5.e3.PubMedCrossRef
44.
Beiser AS, Takahashi M, Baker AL, Sundel RP, Newburger JW. A predictive instrument for coronary artery aneurysms in Kawasaki disease. US multicenter Kawasaki disease study group. Am J Cardiol. 1998;81(9):1116–20.PubMedCrossRef
45.
Honkanen VE, McCrindle BW, Laxer RM, Feldman BM, Schneider R, Silverman ED. Clinical relevance of the risk factors for coronary artery inflammation in Kawasaki disease. Pediatr Cardiol. 2003;24(2):122–6.PubMedCrossRef
46.
Morikawa Y, Ohashi Y, Harada K, Asai T, Okawa S, Nagashima M, et al. Coronary risks after high-dose gamma-globulin in children with Kawasaki disease. Pediatr Int. 2000;42(5):464–9.PubMedCrossRef
47.
McCrindle BW, Li JS, Minich LL, Colan SD, Atz AM, Takahashi M, et al. Coronary artery involvement in children with Kawasaki disease: risk factors from analysis of serial normalized measurements. Circulation. 2007;116(2):174–9.PubMedCrossRef
48.
Piram M, Darce Bello M, Tellier S, Di Filippo S, Boralevi F, Madhi F, et al. Defining the risk of first intravenous immunoglobulin unresponsiveness in non-Asian patients with Kawasaki disease. Sci Rep. 2020;10(1):3125.PubMedPubMedCentralCrossRef
49.
Friedman KG, Jone PN. Update on the Management of Kawasaki Disease. Pediatr Clin North Am. 2020;67(5):811–9.PubMedCrossRef
50.
Inoue Y, Okada Y, Shinohara M, Kobayashi T, Kobayashi T, Tomomasa T, et al. A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. J Pediatr. 2006;149(3):336–41.PubMedCrossRef
51.
Hashino K, Ishii M, Iemura M, Akagi T, Kato H. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int. 2001;43(3):211–7.PubMedCrossRef
52.
Ogata S, Bando Y, Kimura S, Ando H, Nakahata Y, Ogihara Y, et al. The strategy of immune globulin resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. J Cardiol. 2009;53(1):15–9.PubMedCrossRef
53.
Newburger JW, Sleeper LA, McCrindle BW, Minich LL, Gersony W, Vetter VL, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med. 2007;356(7):663–75.PubMedCrossRef
54.
Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet. 2012;379(9826):1613–20.PubMedCrossRef
55.
Dominguez SR, Anderson MS. Advances in the treatment of Kawasaki disease. Curr Opin Pediatr. 2013;25(1):103–9.PubMedCrossRef
56.
Chen S, Dong Y, Kiuchi MG, Wang J, Li R, Ling Z, et al. Coronary artery complication in Kawasaki disease and the importance of early intervention : a systematic review and meta-analysis. JAMA Pediatr. 2016;170(12):1156–63.PubMedCrossRef
57.
Eleftheriou D, Moraes YC, Purvis C, Pursell M, Morillas MM, Kahn R, et al. Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol. Trials. 2023;24(1):60.PubMedPubMedCentralCrossRef
58.
Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993;30(16):1443–53.PubMedCrossRef
59.
Matsubara T, Furukawa S, Yabuta K. Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol. 1990;56(1):29–36.PubMedCrossRef
60.
Burns JC, Mason WH, Hauger SB, Janai H, Bastian JF, Wohrley JD, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr. 2005;146(5):662–7.PubMedCrossRef
61.
Song MS, Lee SB, Sohn S, Oh JH, Yoon KL, Han JW, et al. Infliximab treatment for refractory kawasaki disease in korean children. Korean Circ J. 2010;40(7):334–8.PubMedPubMedCentralCrossRef
62.
Youn Y, Kim J, Hong YM, Sohn S. Infliximab as the first retreatment in patients with Kawasaki disease resistant to initial intravenous immunoglobulin. Pediatr Infect Dis J. 2016;35(4):457–9.PubMedCrossRef
63.
Tremoulet AH, Jain S, Jaggi P, Jimenez-Fernandez S, Pancheri JM, Sun X, et al. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet. 2014;383(9930):1731–8.PubMedCrossRef
64.
Jone PN, Anderson MS, Mulvahill MJ, Heizer H, Glodé MP, Dominguez SR. Infliximab plus intravenous immunoglobulin (IVIG) versus IVIG alone as initial therapy in children with Kawasaki disease presenting with coronary artery lesions: is dual therapy more effective? Pediatr Infect Dis J. 2018;37(10):976–80.PubMedPubMedCentralCrossRef
65.
Miyata K, Bainto EV, Sun X, Jain S, Dummer KB, Burns JC, et al. Infliximab for intensification of primary therapy for patients with Kawasaki disease and coronary artery aneurysms at diagnosis. Arch Dis Child. 2023;108(10):833–8.PubMedCrossRef
66.
Saneeymehri S, Baker K, So TY. Overview of pharmacological treatment options for pediatric patients with refractory Kawasaki disease. J Pediatr Pharmacol Ther. 2015;20(3):163–77.PubMedPubMedCentral
67.
Hamada H, Suzuki H, Onouchi Y, Ebata R, Terai M, Fuse S, et al. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial. Lancet. 2019;393(10176):1128–37.PubMedCrossRef
68.
Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canadian Kawasaki syndrome study group. Pediatr Infect Dis J. 1998;17(12):1144–8.PubMedCrossRef
69.
Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr. 1997;131(6):888–93.PubMedCrossRef
70.
Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child. 2008;93(2):142–6.PubMedCrossRef
71.
Kobayashi T, Kobayashi T, Morikawa A, Ikeda K, Seki M, Shimoyama S, et al. Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease. J Pediatr. 2013;163(2):521–6.PubMedCrossRef
72.
Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2008;153(6):833–8.PubMedPubMedCentralCrossRef
73.
Son MB, Gauvreau K, Burns JC, Corinaldesi E, Tremoulet AH, Watson VE, et al. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: a retrospective study. J Pediatr. 2011;158(4):644-9.e1.PubMedCrossRef
74.
Tremoulet AH, Pancoast P, Franco A, Bujold M, Shimizu C, Onouchi Y, et al. Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2012;161(3):506-12.e1.PubMedPubMedCentralCrossRef
75.
Suzuki H, Terai M, Hamada H, Honda T, Suenaga T, Takeuchi T, et al. Cyclosporin a treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin. Pediatr Infect Dis J. 2011;30(10):871–6.PubMedCrossRef
76.
Buda P, Friedman-Gruszczynska J, Ksiazyk J. Anti-inflammatory treatment of Kawasaki disease: comparison of current guidelines and perspectives. Front Med (Lausanne). 2021;8:738850.PubMedCrossRef
77.
Hoang LT, Shimizu C, Ling L, Naim AN, Khor CC, Tremoulet AH, et al. Global gene expression profiling identifies new therapeutic targets in acute Kawasaki disease. Genome Med. 2014;6(11):541.PubMedPubMedCentralCrossRef
78.
Ferrara G, Giani T, Caparello MC, Farella C, Gamalero L, Cimaz R. Anakinra for treatment-resistant Kawasaki disease: evidence from a literature review. Paediatr Drugs. 2020;22(6):645–52.PubMedPubMedCentralCrossRef
79.
Kone-Paut I, Tellier S, Belot A, Brochard K, Guitton C, Marie I, et al. Phase II open label study of Anakinra in intravenous immunoglobulin-resistant Kawasaki disease. Arthritis Rheumatol. 2021;73(1):151–61.PubMedCrossRef
80.
Yang J, Jain S, Capparelli EV, Best BM, Son MB, Baker A, et al. Anakinra treatment in patients with acute Kawasaki disease with coronary artery aneurysms: a phase I/IIa trial. J Pediatr. 2022;243:173-80.e8.PubMedCrossRef
81.
82.
de La Harpe M, di Bernardo S, Hofer M, Sekarski N. Thirty years of Kawasaki disease: a single-center study at the University Hospital of Lausanne. Front Pediatr. 2019;7:11.PubMedCrossRef
83.
Hayasaka S, Nakamura Y, Yashiro M, Uehara R, Oki I, Tajimi M, et al. Analyses of fatal cases of Kawasaki disease in Japan using vital statistical data over 27 years. J Epidemiol. 2003;13(5):246–50.PubMedCrossRef
Metadaten
Titel
Updates in the Treatment of Kawasaki Disease
verfasst von
Bessey Geevarghese
Publikationsdatum
01.12.2025
Verlag
Springer International Publishing
Erschienen in
Current Treatment Options in Pediatrics / Ausgabe 1/2025
Elektronische ISSN: 2198-6088
DOI
https://doi.org/10.1007/s40746-024-00322-4

Weitere Artikel der Ausgabe 1/2025

Pediatric Headache Management in the Emergency Department: A Review of Challenges and Solutions

  • Open Access
  • Hot Topic

The Effectiveness of Virtual Reality Therapy in Improving Motor Function and Quality of Life among Children with Cerebral Palsy

  • Hot Topic

Reducing Central Line-Associated Bloodstream Infections in a Pediatric CICU: A Review

  • Open Access
  • Cardiology/CT Surgery (K Gist, Section Editor)

Advancements in Treatment Options for Primary Nocturnal Enuresis

  • Pediatric Urology (A Buchanan and G Campbell, Section Editors)

Periorbital and Orbital Cellulitis in Pediatric Emergency Medicine: Diagnostic Challenges and Evidence-Based Guidance

  • Open Access
  • Hot Topic

Correction to: Diagnosis and Management of Pediatric Varicocele: A Modern Update for the Practicing Pediatrician

  • Open Access
  • Correction

Kompaktes Leitlinien-Wissen Pädiatrie (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Pädiatrie

Weniger Bargeld, weniger Erstickungsnotfälle?

Dadurch, dass immer seltener mit Bargeld gezahlt wird, könnte die Rate an Erstickungsnotfällen bei Kindern zurückgehen. Dieser Hypothese ist ein britisches Forschungsteam in Klinikdaten aus den letzten zweieinhalb Jahrzehnten nachgegangen.

Pneumonie ausschließen: Auf das Röntgenbild ist offenbar Verlass

Das Thoraxröntgen ist gemäß Daten aus den USA eine zuverlässige Methode, um bei Kindern in der Notaufnahme rasch eine Lungenentzündung auszuschließen. Zur Vorsicht rät das Ärzteteam jedoch bei bestimmten klinischen Symptomen.

Kawasaki-Syndrom: Kein ASS mehr in der Akutphase?

Um Kinder mit Kawasaki-Syndrom vor entzündlich bedingten Veränderungen der Koronarien zu bewahren, werden sie in der Akutphase mit intravenösen Immunglobulinen und hochdosierter Acetylsalicylsäure (ASS) behandelt. Neuesten Daten zufolge könnte womöglich auf ASS verzichtet werden.

Neurologische Entwicklung von Kindern: Welchen Einfluss hat Stillen?

Stillen bringt zahlreiche gesundheitliche Vorteile mit sich. Ob dazu auch ein niedrigeres Risiko für Entwicklungsverzögerungen und -störungen gehört, hat nun eine israelische Studie untersucht.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise